Last 45 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 14.13 | — | — | 0.59 | 1.07 | 4.38 | — | 3.21 | 31.25 | 8.74 | — | — | — |
| — | — | — | -81.6% | -96.6% | -49.8% | — | — | — | — | — | — | — | |
| P/S Ratio | 3.11 | 22.07 | 3.93 | 0.27 | 0.54 | 0.75 | 1.03 | 1.09 | 0.98 | 0.99 | 1.16 | 1.06 | 1.32 |
| — | +2835.2% | +280.9% | -75.0% | -44.8% | -24.1% | -10.9% | +2.1% | -25.5% | -53.8% | -50.4% | -78.0% | -63.2% | |
| P/B Ratio | — | 4.90 | 2.44 | 2.21 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | 2.69 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 15.00 | — | — | 0.17 | 0.74 | 3.89 | — | 3.23 | — | 1.87 | — | — | — |
| — | — | — | -94.6% | — | +108.1% | — | — | — | — | — | — | — | |
| EV / EBIT | 16.06 | — | — | 0.18 | 0.76 | 4.29 | — | 3.36 | — | 4.02 | — | — | — |
| — | — | — | -94.8% | — | +6.7% | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
CytomX Therapeutics, Inc.'s operating margin was -264.4% in Q3 2025, down 257.5 pp QoQ and down 276.7 pp YoY. This marks the 4th consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of -45.1% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 94.6% | 93.8% | 93.6% | 100.0% |
| — | 0.0% | 0.0% | 0.0% | 0.0% | +5.7% | +6.6% | +6.8% | 0.0% | +9.1% | -6.2% | -6.4% | +8.1% | |
| Operating Margin | 18.1% | -264.4% | -6.9% | 44.4% | 46.4% | 12.3% | -33.7% | 28.1% | -2.3% | 42.0% | -13.5% | -24.1% | -47.2% |
| — | -2250.4% | +79.5% | +58.0% | +2137.7% | -70.8% | -148.5% | +216.9% | +95.2% | +115.8% | +94.2% | +93.2% | +64.6% | |
| Net Margin | 23.1% | -238.6% | -0.8% | 46.2% | 49.6% | 17.2% | -26.0% | 33.3% | 3.1% | 11.3% | -4.4% | -14.1% | -43.6% |
| — | -1490.8% | +96.8% | +38.9% | +1475.2% | +51.3% | -491.8% | +336.1% | +107.2% | +104.3% | +98.1% | +96.0% | +67.2% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | -12.5% | -0.2% | 191.3% | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| ROA | 19.8% | -8.5% | -0.1% | 21.5% | 14.5% | 3.8% | -3.8% | 7.1% | 0.4% | 1.4% | -0.5% | -1.3% | -3.6% |
| — | -321.9% | +97.0% | +201.0% | +3575.4% | +176.7% | -675.8% | +634.0% | +111.0% | +111.6% | +95.4% | +86.7% | +51.2% | |
| ROIC | — | -15.1% | -3.0% | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 249.2% YoY to 3.64x, strengthening the short-term liquidity position. Debt/Equity has declined for 3 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | 0.05 | 0.06 | 0.33 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | 0.35 | — | — | 0.35 | 0.52 | 2.33 | — | 1.06 | — | 1.20 | — | — | — |
| — | — | — | -66.6% | — | +94.1% | — | — | — | — | — | — | — | |
| Current Ratio | 1.25 | 3.64 | 4.20 | 1.73 | 1.25 | 1.04 | 1.00 | 1.16 | 1.17 | 1.37 | 1.33 | 1.40 | 1.55 |
| — | +249.2% | +319.1% | +49.1% | +6.6% | -24.0% | -24.6% | -17.5% | -24.5% | -33.0% | -43.3% | -46.3% | -61.0% | |
| Quick Ratio | 1.25 | 3.64 | 4.20 | 1.73 | 1.25 | 1.04 | 1.00 | 1.16 | 1.17 | 1.37 | 1.33 | 1.40 | 1.55 |
| — | +249.2% | +319.1% | +49.1% | +6.6% | -24.0% | -24.6% | -17.5% | -24.5% | -33.0% | -43.3% | -46.3% | -61.0% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 45 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonCytomX Therapeutics, Inc.'s current P/E is 14.1x. The average P/E over the last 2 quarters is 0.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
CytomX Therapeutics, Inc.'s current operating margin is 18.1%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking CytomX Therapeutics, Inc.'s business trajectory between earnings reports.